# Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma

> **NCT06994572** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Captor Therapeutics S.A.** · enrollment: 141 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** CT-01
- **DRUG:** EVEROLIMUS

## Key facts

- **NCT ID:** NCT06994572
- **Lead sponsor:** Captor Therapeutics S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-26
- **Primary completion:** 2029-04-16
- **Final completion:** 2030-04-01
- **Target enrollment:** 141 (ESTIMATED)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06994572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06994572, "Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06994572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*